Shares in UK-based biopharma Hemogenyx Pharmaceuticals (LSE: HEMO) closed 18% higher on Monday.
The firm earlier announced that its chimeric bait receptor (CBR) platform can potentially be used in the treatment of cancers, in addition to the viral diseases extensively reported by the company to date.
Hemogenyx claims to have demonstrated that human macrophages, a type of immune cells, programmed with a purpose designed CBR, were able to eliminate non-Hodgkin lymphoma (NHL)-derived cells with high efficiency in vitro.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze